International Isotopes Inc. is a nuclear-focused company that specializes in producing, distributing, and selling nuclear materials and isotopes, managing nuclear and radiological products and services, and licensing nuclear technologies.

# Company Overview: International Isotopes Inc.

**Company Name:** International Isotopes Inc.

**Location:** 4137 Commerce Circle, Idaho Falls, Idaho 83401

**Type:** Publicly traded company (Small reporting company and emerging growth company)

---

## Business Focus and Activities

- **Core Operations:** 
  - Specializes in the production, distribution, and sale of nuclear materials and isotopes.
  - Involves handling radioactive materials and nuclear fuel processing.
  - Engaged in licensing and regulatory compliance related to nuclear materials, including NRC licensing.
  - Develops and manages nuclear and radiological products and services, including radiopharmaceuticals and nuclear waste management.

- **Strategic and Revenue-Generating Activities:**
  - Ownership and operation of isotopic production facilities.
  - Licensing of nuclear technologies and processes.
  - Processing of uranium de-conversion and fluorine extraction (not explicitly detailed but referenced in agreements).

---

## Operational details

- **Number of Employees:** Not explicitly specified in the provided documentation.
  
- **Number of Customers:** Not explicitly specified in the provided documentation.

- **Revenue and Income:** 
  - Not explicitly disclosed in the provided excerpt.
  - Financial details such as revenue, net income, or operating income are not provided in this filing.

---

## Regulatory and Licensing

- Maintains a Nuclear Regulatory Commission (NRC) license for operations in Idaho.
- Has submitted amendments to licensing and permits for additional facilities, such as a uranium de-conversion and fluorine extraction processing plant.
- Oversees radiation safety, regulatory compliance, and licensing programs through a Radiation Safety and Regulatory Manager.

---

## Shareholder and Market Data

- **Market Capitalization (as of June 30, 2024):** Approximately $6 million, based on the average bid and ask prices.
- **Shares Outstanding:** 526,266,791 as of April 28, 2025.
- **Major Shareholders:** 
  - Kennerman Associates Inc. (doing business as Kershner Grosso & Co.) holds 42.4% of shares.
  - John M. McCormack and related parties hold about 20.7%.
  - Other significant shareholders include directors and officers, with smaller holdings.

---

## Summary

International Isotopes Inc. is a nuclear-focused company primarily involved in the development and sale of radioactive and nuclear materials, licensing of nuclear technologies, and regulatory compliance within the nuclear industry. The company’s financial metrics such as revenue and income are not disclosed in the provided excerpt. It operates under NRC licenses, and its market value is approximately $6 million with a significant shareholding concentration among a few major shareholders.

International Isotopes Inc. is a Texas-based corporation specializing in the production of isotopes and radiochemicals for healthcare, industrial, and research applications.

# International Isotopes Inc. Overview

## Company Overview
International Isotopes Inc. is a Texas-based corporation formed in 1995. The company specializes in the production of isotopes and radiochemicals for various applications, focusing on healthcare, industrial, and research sectors. They operate primarily through four reportable segments: 

1. **Theranostics Products** (formerly Radiochemical Products)
2. **Cobalt Products**
3. **Nuclear Medicine Standards**
4. **Fluorine Products**

### Key Products
- **FDA Approved Sodium Iodide I-131**: The only generic product of its kind manufactured in the U.S., used for treating hyperthyroidism and thyroid carcinoma.
- **Cobalt-60 Products**: Used in radiation therapy and various industrial applications.
- **Nuclear Medicine Calibration Standards**: Used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging.
- **Medical Devices**: New segment planned for 2024, based on the acquisition of assets from AMICI, Inc.

### Financial Performance
- **Revenue**: Achieved $12.3 million in total revenues in 2023, marking a record high with an increase of $1,085,397 (10%) from the previous year.
- **Sales Growth**:
  - Theranostics Products segment revenue increased by 13% primarily due to higher sales of the FDA-approved sodium iodide I-131.
  - Nuclear Medicine Standards sales grew by 10% during the same period.
- **Net Loss**: Cumulatively, the company has incurred net losses totaling approximately $127.3 million since inception.

### Operations
- **Employees**: The company employs 40 individuals, with 39 in full-time roles.
- **Customer Base**: International Isotopes has over 5,000 nuclear medicine centers in the U.S. that require nuclear medicine products regularly. The company generated approximately 22% of its total gross revenues in 2023 from its three largest customers.

### Regulatory Compliance
International Isotopes Inc. operates under strict government regulations, including:
- **Nuclear Regulatory Commission (NRC) Licenses**: Two active licenses covering a range of operations, including radioisotope processing and waste management.
- **FDA Registration**: Certified as a medical device manufacturer and registered for drug manufacturing.
- **Environmental Compliance**: Adherence to various environmental laws, including the Low-Level Radioactive Waste (LLRW) Policy Act and the Resource Conservation and Recovery Act (RCRA).

### Future Plans and Developments
- Plans to initiate a **Medical Devices** segment starting in 2024.
- Pursuing additional drug opportunities within the Theranostics segmentation.
- Anticipated closure of the asset sale for the Fluorine Products segment within 12 to 24 months from February 2024.

## Summary
International Isotopes Inc. stands at the intersection of healthcare and nuclear chemistry, leveraging its unique offerings to serve a diverse clientele while navigating a complex regulatory landscape. Their focus on growth, profitability, and compliance positions them strategically within their industry.

INTERNATIONAL ISOTOPES INC

10-K / April 30, 2025

10-K / March 29, 2024

10-K / April 30, 2025

Company Overview: International Isotopes Inc.

Business Focus and Activities

Operational details

Regulatory and Licensing

Shareholder and Market Data

Summary